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SUMMARY
 
A differential immunoscreening of the 
 
λ
 
gt11
 
 Plasmodium
falciparum 
 
genomic expression library was carried out using
anti-
 
P. yoelii 
 
sera (convalescent-phase mouse sera) and immune
sera collected from healthy adults, to identify novel cross-reactive
and possibly protective antigens of the parasite. One clone,
with an insert size of 1132 bp that reacted strongly with both
the sera was selected. The insert was found to be a part of
the
 
 P. falciparum 
 
karyopherin 
 
β
 
 (PfK
 
β
 
) homologue. RT-PCR
and Northern blot analysis confirmed the expression of PfK
 
β
 
in the blood stages of the parasite. The 
 
∼
 
110 kDa protein was
localized in the cytoplasm at the ring and trophozoite, and in
the parasitophorous vacuole at the schizont stage. Two large
fragments of PfK
 
β
 
 representing the N- and C-terminal halves
were expressed in
 
 E. coli
 
. The recombinant proteins were
highly immunogenic in mice, and also found to be the target
for immune response in natural infections of
 
 Plasmodium 
 
spp.
Anti-sera against the protein showed a low level of anti-parasitic
activity. Immunization with recombinant PfK
 
β
 
 fragments was
only partially protective against a heterologous challenge infection
in mice. Our results show that the parasite releases a highly
immunogenic, cytoplasmic protein into the host which may not
contribute to the development of protective immunity.
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RESEARCH NOTE
 
Malaria remains as one of the leading causes of morbidity
and mortality, and there are an estimated 300–500 million
cases resulting in over a million deaths every year globally (1).
To control malaria, improved tools must be developed and
in this context a tool such as a vaccine is necessary because
of the massive disease burden of malaria in the developing
world. However, malaria vaccine development is a formida-
ble challenge, due to poor understanding of the protective
immune mechanism and lack of characterization of appro-
priate vaccine candidate antigens (2). Selection of parasite
proteins as vaccine candidates is usually based upon their
location in the parasite, immunogenicity and conservation
among different 
 
Plasmodium
 
 species. However the high anti-
genic polymorphism in malarial parasite antigens and lack
of a suitable animal model for human malaria parasites are
major hurdles in the path of malaria vaccine development
(2). Several of the currently used vaccine target antigens
were first developed by characterizing homologues of
 
P. falciparum
 
 in murine malaria, 
 
P. berghei
 
 and 
 
P. yoelii
 
, and
testing their efficacy as vaccine candidates in a mouse chal-
lenge model. The existence of conserved antigen analogues
across the 
 
Plasmodium
 
 species has been demonstrated by
cross-hybridization and by comparison of the amino acid
sequences of different parasite proteins (3–6). Identification
of such cross-reactive antigens that are conserved in different
 
Plasmodium
 
 species may allow evaluation of their potential
as vaccine candidates in the murine malaria model; lack of
a validated animal model is one of the major hurdles in
characterization of protective antigens of the human malarias,
 
P. falciparum
 
 and 
 
P. vivax
 
. The present study was undertaken
with a view to characterize conserved malaria protein(s),
which might be involved in the build-up of protective anti-
body response to 
 
P. yoelii
 
 infection in convalescent mice, and
in healthy individuals living in a 
 
P. falciparum
 
 endemic area.
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An expression library of 
 
P. falciparum
 
 (3D7) genomic DNA
was constructed in 
 
λ
 
gt11 following Snyder 
 
et al
 
. (7). The
rodent malaria parasites, 
 
P. yoelii nigeriensis
 
, were maintained
in BALB/c mice and the convalescent-phase mouse anti-
 
P. yoelii
 
 serum was obtained after repeated 
 
P. yoelii
 
 infection
and cure of the BALB/c mice (6). Human sera from healthy
adults were obtained from residents of the Koraput district
of Orissa, a highly 
 
P. falciparum
 
 endemic region of India (8).
Serum samples were also collected from healthy individuals
who had no known history of malaria and were used as neg-
ative control. The protocol for this study was approved by
the Human Volunteer Research Ethical Committee of
the International Centre for Genetic Engineering and Bio-
technology, New Delhi, India.
The expression library was probed by immunoscreening
with hyper-immune anti-
 
P. yoelii
 
 sera following Snyder 
 
et al
 
.
(7). Twenty phage plaques that reacted with the sera were
then immunoscreened with the pooled human sera collected
from 
 
P. falciparum
 
 endemic areas. We identified one of the
clones (KP1) that reacted strongly with both the sera, sug-
gesting that it may represent some conserved, cross-reactive
and immunogenic antigen(s). The phage DNA was prepared
from the KP1 clone and digested with 
 
Eco
 
RI to release the
insert. The released insert (1132 bp) showed a continuous
reading frame. In Southern blot analysis using KP1 insert as
the probe, a hybridization band of 
 
∼
 
1·1 kb was detected with
 
P. falciparum
 
 DNA digested with 
 
Eco
 
RI, whereas the same
probe did not hybridize with human DNA. A 
 
∼
 
4·4 kb band
was detected in Northern blot analysis using total parasite
RNA and the KP1 insert as probe. A fragment of 1·1 kb was
amplified by RT-PCR using total RNA of  
 
P. falciparum
 
with terminal primers corresponding to KP1 insert sequences
(data not shown). Together, these results indicated that the
cloned insert was derived from 
 
P. falciparum
 
 and is expressed
during the blood stages of the parasites.
A BLAST search at GenBank, using a sequence of the KP1
clone showed that the deduced amino acid sequence had sig-
nificant homology with karyopherin 
 
β
 
 proteins of different
organisms. The cloned segment was found to be located
on chromosome 5 of 
 
P. falciparum
 
 using the 
 
Plasmodium
 
genome database at PlasmoDB (
 
www.plasmodb.org
 
). The
ORF finder and gene finder programs identified a 3372 bp
long gene sequence containing the sequences of the KP clone.
This gene sequence encodes a putative translation product
of 1124 aa and has been identified earlier as the 
 
P. falciparum
 
homologue of karyopherin 
 
β
 
 (PfK
 
β
 
) (9), which showed 24%
identity and 21% similarity with the 
 
Homo sapiens
 
 karyo-
pherin 
 
β
 
3 protein, and 20% identity and 22% similarity with
 
Saccharomyces cerevisiae
 
 karyopherin 
 
β
 
3. A homologue
of the PfK
 
β
 
 sequence was also found by BLAST search of
the 
 
P. yoelii
 
 genome database on contig chrPy_1_cpy42. The
gene finder program identified a 3363 bp long ORF on this
contig. The deduced amino sequence showed 83% identity
and 10% similarity with that of PfK
 
β
 
. The complete PfK
 
β
 
gene was PCR-amplified from 
 
P. falciparum
 
 genomic DNA
and sequenced, and it matched fully with the sequence avail-
able in the database.
The full length PfK
 
β
 
 gene was cloned in pGEX and
pQE30 vectors to express the recombinant protein as a GST
fusion protein or with a histidine tag at the N-terminal,
respectively. However, even after several attempts using
different expression conditions we were unable to produce
sufficient amounts of the full length recombinant purified
protein. Therefore, the N-terminal (aa 1–576; PfK
 
β
 
-
 
Ν
 
) and
C-terminal (aa 524–1127; PfK
 
β
 
-C) (Figure 1a) halves were
cloned into pQE31 expression vector and the corresponding
recombinant proteins were expressed with 6 
 
×
 
 histidine tags
in 
 
E. coli
 
. For expression and purification of the recombinant
proteins corresponding to PfK
 
β
 
-N and PfK
 
β
 
-C fragments,
 
E. coli
 
 M15 cells containing the recombinant plasmids were
grown in LB and induced for protein expression with 1 m
 

 
IPTG for 5 h at 37
 
°
 
C. The harvested cell pellet in each case
was suspended in lysis buffer (10 m
 

 
 Tris-HCl PH8·0, 5 m
 

 
benzamidine-HCl, 2 m
 

 
 PMSF, 100 m
 

 
 NaCl, 200 
 
µ
 
g /mL
lysozyme, 0·1% Tween 20) and lysed by sonication. In each
case the recombinant protein was found to be expressed in
the inclusion bodies. Inclusion bodies were collected by
centrifugation of lysed cells at 12 000 
 
g
 
 for 30 min at 4
 
°
 
C. The
pellet was solubilized in 8 
 

 
 urea in TBS (25 m
 

 
 Tris-HCl
pH 8·0, 500 m
 

 
 NaCl) and the insoluble material was
removed by centrifugation. The 6 
 
×
 
 his-tagged protein in the
supernatant was purified using nickel-nitrilotriacetic acid
(Ni-NTA) resin (Qiagen) and refolded by serial dialysis in a
step gradient of urea in the presence of 1 m
 

 
 of  reduced and
oxidized glutathione (GSH and GSSG). The refolded pro-
tein was further purified by ion exchange chromatography
using a Q-sepharose column. Purity of the protein was judged
by SDS-PAGE and protein concentration was estimated by
using Bradford reagent (Bio-Rad Laboratories, CA). Two
recombinant proteins of 
 
∼
 
62 kDa and 
 
∼
 
60 kDa sizes corre-
sponding to PfK
 
β
 
-N and PfK
 
β
 
-C fragments, respectively,
were purified to homogeneity (Figure 1b). Both purified
protein fragments cross-reacted in an immunoblot assay with
the convalescent mouse anti-
 
P. yoelii
 
 sera as well as with the
pooled human sera, which were used initially for the library
screening (Figure 1c,d); no recognition was found with
normal human and mice sera. These results confirm the
presence of antibodies in these sera against the expressed
proteins.
Antibody response against PfK
 
β
 
 was analysed in human
sera samples from 
 
P. falciparum
 
 endemic areas, using the
recombinant proteins by enzyme-linked immunosorbent assay
(ELISA). All the 20 sera samples analysed showed reactivity
at 1 : 200 dilutions with both PfK
 
β
 
-N and PfK
 
β
 
-C (Figure 1e).
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The sera from individuals who have never been exposed to
malaria showed no or insignificant antibody response. Anti-
body response in sera from mice infected with 
 
P. yoelii
 
 and
 
P. berghei
 
, and rhesus monkeys infected with 
 
P. cynomolgi
 
,
were also analysed. Both anti-
 
P. yoelii
 
 and anti-
 
P. berghei
 
 sera
showed significant response at 1 : 200 dilution with PfK
 
β
 
-N
and PfK
 
β
 
-C as capture antigen (0·6–1·0 OD). Monkey
anti-
 
P. cynomolgi
 
 sera showed somewhat lower reactivity
(0·35–0·4 OD). These results suggested that the conserved
karyopherin 
 
β
 
 is also a target of antibody response during the
infections with these plasmodia species.
In order to analyse immune response of the recombinant
PfK
 
β
 
 fragments in animals, two groups of female BALB/c
mice (6 weeks old, five mice per group) were immunized
intraperitoneally with 30 
 
µ
 
g of purified PfK
 
β
 
-N and PfK
 
β
 
-
C recombinant proteins emulsified in complete Freund’s
adjuvant. Two booster immunizations with the same antigen
in incomplete Freund’s adjuvant were given after 21 and 42
days. One set of five mice was also immunized with adjuvant
alone, according to the same schedule, to act as control. Sera
samples were collected from these mice on days 0, 14, 28, 42
and 56. Sera from immunized mice (after the second booster)
gave end-point titres of 1 : 205 600 and 1 : 411 200 for PfK
 
β
 
-
N and PfK
 
β
 
-C, respectively, suggesting that both the recom-
binant proteins are highly immunogenic, and harbour B and
T cell epitopes. These PfK
 
β
 
 antibodies also cross-reacted with
the 
 
P. falciparum
 
 and 
 
P. yoelii
 
 parasite lysate on the immuno-
blot and detected the 
 
∼
 
110 kDa protein band (Figure 1f,g).
No cross-reaction of the parasite lysates was observed with
pre-immune sera.
A large number of surface proteins of the malaria parasite
or of the infected erythrocytes have been shown to be immuno-
genic and able to generate protective immunity in animal
models of malaria (reviewed in 10,11). Identification of a
presumably cytoplasmic protein like PfK
 
β, as a parasite antigen
that induces high immune response during the course of
Figure 1 (a) Schematic representation of the 
full PfKβ gene, different functional domains 
[Importin beta N-terminal region (IBN-
NT), HEAT and armadillo (ARM) repeats] 
and respective amino acid positions are 
indicated (9); the N-terminal (PfKβ-N) and 
C-terminal (PfKβ-C) regions expressed as 
recombinant proteins are also marked. 
(b) Purified recombinant PfKβ-N (lane 1) 
and PfKβ-C (lane 2) proteins; Western blots 
of the gel run in parallel with (c) endemic 
human sera and (d) convalescent mice 
anti-P. yoelii sera. (e) Scatter plot representing 
ELISA results using sera from individuals 
residing in P. falciparum endemic areas; each 
serum was diluted 1 : 200 and tested in 
triplicate against recombinant PfKβ-N 
and PfKβ-C, recombinant MSP119 was kept 
as positive control. The cross bars indicate 
median of the reactivity with different 
sera. (f–g) Western blot analysis of 
(f ) P. falciparum and (g) P. yoelii parasite lysate 
showing karyopherin β protein recognized 
with mice anti PfKβ sera. (h) Survival 
period of mice in different immunization 
groups challenged intravenously with 
1 × 10 000 P. yoelii nigeriensis parasitized 
erythrocytes; each dot represents the time 
point of the death of a mouse.
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natural infection, may appear somewhat surprising, and in
contrast to the above studies. However, in a study somewhat
similar to the present one, Lobe et al. (12) screened the cDNA
expression library of P. falciparum using sera from malaria-
immune persons and identified a ribosomal phosphoprotein
P0 of the parasite as one of the major antigens inducing
high antibody titres in these sera. Ribosomal phosphopro-
tein P0 is expected to be an internal protein with a role in
ribosomal assemblage (13). However, a transient surface
localization of P0 on the merozoite surface has been impli-
cated (14).
Karyopherin β plays a central role in nuclear transport;
proteins bearing nuclear localization sequences (NLS) bind
to the heterodimer consisting of karyopherin α and β for
translocation through the nuclear pore complex (NPC)
(15,16). We have recently shown interaction of PfKβ with
the karyopherin α homologue of the parasite, suggesting its
conserved role in nuclear transport within the parasite (9).
How can PfKβ, which is expected to be a cytoplasmic pro-
tein, generate antibody response during the course of malaria
infection with different plasmodia species? To address this
question we carried out localization studies using anti-PfKβ
antibodies. Results of IFA showed that the protein was
localized in the cytoplasm at the ring and trophozoite stages
(Figure 2a,b), whereas at the schizont stage it was mostly
localized in the parasitophorous vacuole (Figure 2c). To
further confirm the localization of the protein in the parasite
Western blot analysis was carried out with fractionated
infected erythrocytes and schizont/merozoite-stage culture
supernatant. Infected erythrocytes (2 × 107) were fractionated
by treatment with saponin (0·15%), and both the supernatant
and parasite pellets were separated on SDS-PAGE and
Figure 2 Localization of PfKβ by 
immunofluorescence assay. Plasmodium 
falciparum parasites at (a) ring, (b) trophozoite, 
(c) late schizont and (d) merozoite stages 
were immunostained with mouse anti-PfKβ 
sera (red) and visualized with a confocal 
microscope. Schizonts and merozoites 
were also immunostained with anti-MSP1 
antibodies (green); parasite nuclei were 
stained with DAPI (blue). (e) Localization 
of PfKβ in infected erythrocyte fractions by 
immunoblot assay. Infected erythrocytes 
were lysed by saponin, parasite (lane 1) 
and supernatant (lane 2) fractions were 
separated on SDS-PAGE and analysed on 
immunoblot using anti-PfKβ or anti-PfERC 
or antifalcipain-3 antibodies. (f ) Localization 
of PfKβ in culture supernatant by 
immunoblot assay. The parasite pellet 
(lane 1) and the culture supernatant ( lane 2) 
collected from schizont/merozoite-stage 
parasite culture, were analysed on an 
immunoblot using anti-PfKβ, anti-PfERC 
or anti-falcipain-3 antibodies.
© 2005 Blackwell Publishing Ltd, Parasite Immunology, 27, 197–203 201
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analysed on immunoblot using anti-PfKβ antibodies. Schizont/
merozoite-stage culture supernatant was prepared from
P. falciparum 3D7 culture following Goel et al. (17) and also
analysed on immunoblot. These Western blot analyses again
showed the presence of PfKβ protein in the parasitophorous
vacuole at the schizont stage, as well as in the culture sup-
ernatant collected after erythrocyte rupture (Figure 2e,f ).
Antibodies against endoplasmic reticulum resident protein
(PfERC) and a cysteine protease (falcipain-3) were used as
negative controls; bands corresponding to PfERC and
falcipain-3 were detected in the parasite fraction with these
antibodies but were absent in the parasitophorous vacuole
and the culture supernatant (Figure 2e,f ). It may be that the
PfKβ present in the parasitophorous vacuole during the
schizont stage is released in the host environment during
schizont rupture and is exposed to the immune system of
the host, which leads to generation of an immune response
against it. It remains to be analysed if other proteins involved
in nuclear transport are also released from the parasite in a
similar manner. Histidine rich protein II (HRPII), a major
blood-stage P. falciparum protein, is also known to be released
in large amounts in the host plasma (18). The HRPII pro-
tein is transported to the RBC cytoplasm and is released
after host cell rupture (19). Involvement of cytoplasmic
functional proteins in immunity against pathogens is not
limited to P. falciparum alone. For example, a cytoplasmic
urease enzyme and an associated protein, HspB, in Helico-
bacter pyroli have been shown to be the targets of immune
recognition in patients (20). The urease is released by the
bacteria in the host environment in a programmed manner
(21). The recombinant urease and HspB were found to be
immunogenic in animals and are being considered as major
vaccine candidate antigens (22–24).
After confirming the immunogenicity of PfKβ in mice by
immunization and in human as inferred from immunological
observations from clinical isolates, we made an attempt to
assess anti-parasitic activity of anti-PfKβ-N and anti-PfKβ-
C antibodies in vitro culture following Kennedy et al. (25).
Plasmodium falciparum (3D7) parasite cultures were syn-
chronized by sorbitol treatment (26) and the parasitaemia
was adjusted to 1%. These synchronized parasites at late
trophozoite/schizont stages were cultured in 96-well plates with
5%, 10% and 20% of the immune sera from mice immunized
with the antigens or with the adjuvant alone, in triplicate.
After 24 h thin blood smears were prepared and stained
with Giemsa stain and parasitaemia was determined micro-
scopically. Antisera from both the group of immunized mice
showed only 25–37% growth inhibition of parasite in vitro;
these levels of inhibition are considered as insignificant in
these assays. This marginal growth inhibition by anti-PfKβ-
N and anti-PfKβ-C antibodies suggested that antibodies
against theses regions of PfKβ may not be involved in protective
immunity against blood-stage malaria. It has been shown
that antibodies against several malarial proteins or protein
domains do not contribute to protective immunity (27,28).
To assess the protective efficacy of recombinant proteins
PfKβ-N and PfKβ-C against parasite challenge, mice immu-
nized with these antigens were challenged with murine malaria
parasite P. yoelii. The immunized mice (five for each group)
were challenged intravenously with 1 × 10 000 P. yoelii
nigeriensis parasitized erythrocytes. Mice immunized with
adjuvant alone were used as control. Starting from day 1
after the challenge infection, parasitaemia was monitored
every alternate day by microscopic examination of stained
blood films, counting at least 10 000 RBC. All the mice in
control group showed continuous increase in parasitaemia
from days 3–10 post-infection, eventually leading to death
of the animal (Figure 1h). The mice immunized with PfKβ-
N and PfKβ-C and challenged with P. yoelii infection did
not survive the challenge, although there was a considerable
increase in the survival period as compared with the control
mice (Figure 1h), indicating only a partial protection against
the heterologous challenge infection. Taken together these
results suggest that anti-PfKβ antibodies, generated during
the course of malaria infections, may have moderate anti-
parasitic abilities and may contribute to the overall immu-
nity against malaria. However, if  so, then the question of
immune response to a parasite protein somewhat homologous
to the human counterpart (∼24% homology), leading to
autoimmune response may become relevant. The role of
autoimmunity in immune protection against malaria has
been a subject of  debate (29). Presence of  serum auto-
antibodies was first described by Shaper et al. (30) in
malaria-infected individuals, and by Kreier and Dilley (31)
in experimental rat infections. Since then a number of studies
have reported the presence and reactivity of autoantibodies
to DNA, erythrocyte, lymphocyte, phospholipids, ribonucleo-
protein, etc., during the course of acute disease in humans or
in experimental infection in animals (reviewed in 32). It has
been suggested that parasites protect themselves from host
immune response by employing proteins that are either
homologous or are able to mimic host cellular proteins. The
works presented in this report and by earlier workers point
towards generation of immune responses to some malaria
proteins that are homologous to the counterpart host proteins.
It is also known that a number of malaria protein antigens
induce non-protective immune responses, and also that the
malaria parasite generates highly immune evasive ‘smoke-
screen epitopes’ to keep the host immune response busy
(27). Such immune responses may not control the parasite
levels effectively and an effective control occurs only when
immune responses against crucial epitopes are generated.
Presence of  such highly immunogenic molecules on the
parasite surface or release of such molecules during its life
202 © 2005 Blackwell Publishing Ltd, Parasite Immunology, 27, 197–203
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cycle could be one of the immune evasion strategies that the
parasite has developed.
Although the findings of the present study that a conserved
and essentially a cytoplasmic protein is involved in the build-up
of the immune response during malaria infection may be
useful in understanding malaria immunity, the approach of
differential immuno-screening used here may not always lead
to the characterization of malaria proteins that are involved
in protective immunity. At the same time it is also clear that
immune response to malaria proteins is cross-reactive among
the malaria species and may not be limited to the parasite
surface proteins only.
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